Current Hematologic Malignancy Reports

, Volume 8, Issue 3, pp 226–235

Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience

Lymphomas (P McLaughlin, Section Editor)

DOI: 10.1007/s11899-013-0166-1

Cite this article as:
Lange, J. & Burkhardt, B. Curr Hematol Malig Rep (2013) 8: 226. doi:10.1007/s11899-013-0166-1

Abstract

Non-Hodgkin lymphoma (NHL) is amongst the most frequent cancer subtypes in children and in adults. However, there are major differences in the distribution of NHL subtypes between the pediatric and adult patient populations. At least for diffuse large B-cell lymphoma (DLBCL) recent data indicate that patient age at diagnosis correlates with molecular features of the lymphoma. Concerning treatment, in common pediatric protocols the same therapy is used for DLBCL and Burkitt lymphoma/leukemia (BL/B-AL). In adult patients, there is an established gold standard treatment for DLBCL, while the optimal treatment of BL/B-AL is under evaluation. Importantly, the correct diagnosis of the NHL subtype plays a crucial role in the treatment decision in adults with aggressive B-cell lymphoma. Adolescent and young adult patients are caught between the two age groups of children on the one hand and adults on the other. Whether the lymphoma biology and subtypes found in this age group resemble rather their pediatric or their adult counterparts is not yet answered. Also, systematic data on the optimal treatment for adolescents with lymphoma are lacking. Therefore, this article reviews current data on patient characteristics, biology, treatment and outcome, mainly in pediatric patients. These data are compared to those published for adult patients with B-cell NHL aiming to look for hints on optimal classification and treatment in adolescents and young adults with B-NHL.

Keywords

Non-Hodgkin lymphoma Diffuse large B-cell lymphoma Burkitt lymphoma B-NHL Children Adolescents Young adults 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.NHL-BFM Study Center and Department of Pediatric Hematology and OncologyUniversity Children’s HospitalMünsterGermany

Personalised recommendations